Dr. Hossein Maymani, MD

Dr. Maymani practices at Longmont Surgery Center, LLC in Longmont, Colorado.

Dr. Maymani's NPI, 1023303096, was assigned on June 17, 2011. Dr. Maymani graduated from University of North Carolina at Chapel Hill School of Medicine in 2011. Dr. Maymani holds Colorado license DR.0059632.

Dr. Maymani's primary practice is Longmont Surgery Center, LLC, at 2030 Mountain View Ave, Longmont, CO 80501 in Boulder County. The practice phone is (303) 682-0375.

Dr. Maymani's primary practice is Longmont Surgery Center, LLC in Longmont, Colorado. Dr. Maymani is also affiliated with UCHealth Longs Peak Hospital. The medical group on file is Rocky Mountain Cancer Centers. Dmand AI also links Dr. Maymani to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Maymani practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Maymani's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Maymani is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Maymani's licenses on file in 2 states: Colorado and Oklahoma.

CMS data shows 55,548 Medicare services from Dr. Maymani across 66 procedure codes in 2024, for 478 Medicare patients. Medicare paid $827,812 for them. Every service was in an office.

CMS counts 478 Medicare patients who saw Dr. Maymani in 2024. The largest group is 65 to 74, with 224 patients. 60% of them have high blood pressure, and 59% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Maymani's median patient age at 72, with 51% women.

In 2024, Dr. Maymani wrote 897 Medicare Part D claims for 192 patients. 77% of them were for generic drugs. CMS names the drug for 707 of them, across 26 drugs with 11 or more claims each, at $1,336,117 in total drug cost. In 2023, CMS named 593 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 73 out of 100 for Dr. Maymani for performance year 2024, reported through an alternative payment model (APM). Dr. Maymani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Maymani as offering telehealth.

Dmand AI links 7 papers to Dr. Maymani, published from 2014 to 2019. 2014 was the busiest year, with 2. Dr. Maymani's most frequent co-authors are Mohamad Ali Cherry, MD, Borje S. Andersson, MD, PhD and Qaiser Bashir, MD.

Dmand AI links Dr. Maymani to 1 clinical trial. Conditions studied include Carcinoma, Non-Small-Cell Lung and Carcinoma, Bronchogenic.

CMS Open Payments shows 10 general payments to Dr. Maymani from 6 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 76% of the total. Medtronic, Inc. paid the most, $62.

Dr. Maymani graduated from University of North Carolina at Chapel Hill School of Medicine in 2011.